Glargine and degludec: solution behaviour of higher dose synthetic insulins

Adams, Gary G.; Alzahrani, Qushmua; Jiwani, Shahwar I.; Meal, Andrew; Morgan, Paul S.; Coffey, Frank; Kok, Samil; Rowe, Arthur J.; Harding, Stephen E.; Chayen, Naomi; Gillis, Richard B.

doi:10.1038/s41598-017-06642-w

All Outputs (2)

Characterisation of insulin analogues therapeutically available to patients (2018)
Journal Article
Adams, G. G., Meal, A., Morgan, P. S., Alzahrani, Q. E., Zobel, H., Lithgo, R., …Chayen, N. (2018). Characterisation of insulin analogues therapeutically available to patients. PLoS ONE, 13(3), Article e0195010. https://doi.org/10.1371/journal.pone.0195010

The structure and function of clinical dosage insulin and its analogues were assessed. This included ‘native insulins’ (human recombinant, bovine, porcine), ‘fast-acting analogues’ (aspart, glulisine, lispro) and ‘slow-acting analogues’ (glargine, de... Read More about Characterisation of insulin analogues therapeutically available to patients.

Glargine and degludec: solution behaviour of higher dose synthetic insulins (2017)
Journal Article
Adams, G. G., Alzahrani, Q., Jiwani, S. I., Meal, A., Morgan, P. S., Coffey, F., …Gillis, R. B. (2017). Glargine and degludec: solution behaviour of higher dose synthetic insulins. Scientific Reports, 7(1), Article 7287. https://doi.org/10.1038/s41598-017-06642-w

Single, double and triple doses of the synthetic insulins glargine and degludec currently used in patient therapy are characterised using macromolecular hydrodynamic techniques (dynamic light scattering and analytical ultracentrifugation) in an attem... Read More about Glargine and degludec: solution behaviour of higher dose synthetic insulins.